文献速递乳腺乳腺X线USMR

非钙化导管原位癌的影像与病理特征:超声能否预测升级

Imaging and pathologic features of non-calcified ductal carcinoma in situ: can sonography predict upgrade?
PubMed 文献 · Br J Radiol · 2021-12-21

回顾2009年12月至2018年4月经影像引导空芯针活检确诊的导管原位癌,排除钼靶微钙化或同侧同时癌,共71个病灶。62%(44/71)有钼靶表现,38%(27/71)钼靶隐匿者由超声或MRI发现;67例超声中56例(83.6%)见肿块、11例(16.4%)无超声对应。最终手术病理升级率21%(15/71),有超声对应者升级27%(15/56),仅钼靶表现者0%(0/11)。作者认为超声诊断的非钙化导管原位癌可能是升级的独立危险因素。

要点

  • 无微钙化时也应将结构扭曲、不对称、局灶性不对称和肿块纳入导管原位癌鉴别。
  • 超声可见对应病灶者升级率27%(15/56),仅钼靶表现者0%(0/11)。
  • 作者认为超声诊断的非钙化导管原位癌可能是升级的独立危险因素。

核心结论

  • 即使没有微钙化,结构扭曲、不对称、局灶性不对称和肿块也应考虑导管原位癌的鉴别诊断。
  • 超声诊断的非钙化导管原位癌可能是升级的独立危险因素。

研究设计与样本

  • 回顾性研究,纳入2009年12月至2018年4月经影像引导空芯针乳腺活检确诊的导管原位癌患者。
  • 排除钼靶见微钙化或空芯针活检见同侧同时癌者,共71个病灶构成研究队列。
  • 升级定义为手术病理示微浸润癌或浸润癌。

关键影像表现/征象

  • 62%(44/71)病例有钼靶表现,38%(27/71)钼靶隐匿病灶在超声、MRI或两者上有表现。
  • 67例接受超声者中,56/67(83.6%)见肿块,11/67(16.4%)未发现超声对应病灶。

诊断标准与关键数值

  • 21%(15/71)病灶最终手术病理升级。
  • 有超声对应病灶者升级率27%(15/56),仅有钼靶表现者升级率0%(0/11)。

临床应用与阅片要点

  • 放射科医生需认识导管原位癌的影像特征。
  • 当非钙化导管原位癌由超声诊断时,作者认为应考虑升级率增高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study was to evaluate the imaging and pathologic features and upgrade rate of non-calcified ductal carcinoma in situ (NCDCIS). The study tested the hypothesis that lesions with sonographic findings have higher upgrade rate compared to lesions seen on mammography or MRI only.

METHODS: This retrospective study included patients with ductal carcinoma in situ (DCIS) diagnosed by image-guided core breast biopsy from December 2009 to April 2018. Patients with microcalcifications on mammography or concurrent ipsilateral cancer on core biopsy were excluded. An upgrade was defined as surgical pathology showing microinvasive or invasive cancer.

RESULTS: A total of 71 lesions constituted the study cohort. 62% of cases (44/71) had a mammographic finding, and 38% (27/71) of mammographically occult lesions had findings on either ultrasound, MRI, or both. Of the 67 cases that underwent sonography, a mass was noted in 56/67 (83.6%) cases and no sonographic correlate was identified in 11/67 (16.4%) cases. 21% (15/71) of lesions were upgraded on final surgical pathology. The upgrade rate of patients with sonographic correlate was 27% (15/56) vs with mammographic findings only was 0% (0/11).

CONCLUSION: DCIS should be considered in the differential diagnosis of architectural distortion, asymmetries, focal asymmetries, and masses, even in the absence of microcalcifications. NCDCIS diagnosed by ultrasound may be an independent risk factor for upgrade.

ADVANCES IN KNOWLEDGE: Radiologists must be aware of imaging features of DCIS and consider increased upgrade rate when NCDCIS is diagnosed by ultrasound.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Komarla, Gilliland, Piraner, et al. Imaging and pathologic features of non-calcified ductal carcinoma in situ: can sonography predict upgrade? Br J Radiol. 2021. PMID: 34870448. doi:10.1259/bjr.20211013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。